« Back
Home /
Emibetuzumab Biosimilar（Anti-HGFR / c-Met Reference Antibody）

Emibetuzumab Biosimilar（Anti-HGFR / c-Met Reference Antibody）

Item no.	DCC-A174-100mg
Manufacturer	DCChemicals
CASRN	1365287-97-3
Amount	100 mg
Quantity options	100 mg 10 mg 1 mg 5 mg
Category	Neutralization
Applications	NT
Specific against	other
Available
Manufacturer - Applications	Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 100 mg

available

Delivery expected until 10/16/2025

Express Delivery: Save 3 days

Compare

Add to wishlist

Get an offer